Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-06-18

FDA Approved: ENDARI — Supplemental Application (Emmaus Medical, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENDARI (glutamine) from Emmaus Medical, Inc., under a supplemental approval to update/expand the label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ENDARI (GLUTAMINE)

Snippet

SUPPL AP for ENDARI (GLUTAMINE)